Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano

L. Fornazzari; F. Alvarez; H. Gabrielli; A. Sastre; O. Fustinoni; L. Gold; N. Pangre; D. Roselli; A. Roselli; R. Chaskel; R. E. Hernández; A. De Villavicencio Ojeda; M. Grau Vidal; R. Flaskamp; J. R. Castañeda; I. Arocha; P. Rentschler; L. Lemme; C. Lara; E. Merino

Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano

Translated title of the contribution: Efficacy and tolerability of nimodipine in the treatment of Primary Degenerative Dementia and Multiinfarct Dementia. A multicentre latinamerican study

L. Fornazzari, F. Alvarez, H. Gabrielli, A. Sastre, O. Fustinoni, L. Gold, N. Pangre, D. Roselli, A. Roselli, R. Chaskel, R. E. Hernández, A. De Villavicencio Ojeda, M. Grau Vidal, R. Flaskamp, J. R. Castañeda, I. Arocha, P. Rentschler, L. Lemme, C. Lara, E. Merino

Research output: Contribution to journal › Article › peer-review

Abstract

This first multicenter, multinational, latinamerican, open study was designed to evaluate efficacy and safety of nimodipine in patients with Primary Degenerative Dementia-Alzheimer type (PDD-AD) and Multiinfarct Dementia (MID). The study ran for 12 weeks, and at baseline and every 4 weeks, the patients were evaluated with a battery of cognitive tests: Mini Mental State Examination (MMSE) and Trail Making Test (TMT-A), and also behavioral-functional scales like SCAG and RAGS-E. There was a significant difference in the majority of the test performances among baseline and at the end of the study in both groups. This significant improvement was also noticed independently by the caregivers assessed by the RAGS-E scale. The alleviation of behavioral symptoms in both groups, including anxiety, irritability, hostility, and paranoia, particularly in PDD-AD patients, makes us suggest that nimodipine could be used as an effective and safe drug to alleviate cognitive and behavioral symptoms in the two more common causes of dementia world wide.

Translated title of the contribution	Efficacy and tolerability of nimodipine in the treatment of Primary Degenerative Dementia and Multiinfarct Dementia. A multicentre latinamerican study
Original language	Spanish
Pages (from-to)	54-61
Number of pages	8
Journal	Revista Neurologica Argentina
Volume	22
Issue number	2
State	Published - 1997
Externally published	Yes

Cite this

Fornazzari, L., Alvarez, F., Gabrielli, H., Sastre, A., Fustinoni, O., Gold, L., Pangre, N., Roselli, D., Roselli, A., Chaskel, R., Hernández, R. E., De Villavicencio Ojeda, A., Vidal, M. G., Flaskamp, R., Castañeda, J. R., Arocha, I., Rentschler, P., Lemme, L., Lara, C., & Merino, E. (1997). Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano. Revista Neurologica Argentina, 22(2), 54-61.

@article{666b287a5ec44b069dc7f5e3611dc18c,

title = "Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano",

abstract = "This first multicenter, multinational, latinamerican, open study was designed to evaluate efficacy and safety of nimodipine in patients with Primary Degenerative Dementia-Alzheimer type (PDD-AD) and Multiinfarct Dementia (MID). The study ran for 12 weeks, and at baseline and every 4 weeks, the patients were evaluated with a battery of cognitive tests: Mini Mental State Examination (MMSE) and Trail Making Test (TMT-A), and also behavioral-functional scales like SCAG and RAGS-E. There was a significant difference in the majority of the test performances among baseline and at the end of the study in both groups. This significant improvement was also noticed independently by the caregivers assessed by the RAGS-E scale. The alleviation of behavioral symptoms in both groups, including anxiety, irritability, hostility, and paranoia, particularly in PDD-AD patients, makes us suggest that nimodipine could be used as an effective and safe drug to alleviate cognitive and behavioral symptoms in the two more common causes of dementia world wide.",

author = "L. Fornazzari and F. Alvarez and H. Gabrielli and A. Sastre and O. Fustinoni and L. Gold and N. Pangre and D. Roselli and A. Roselli and R. Chaskel and Hern{\'a}ndez, {R. E.} and {De Villavicencio Ojeda}, A. and Vidal, {M. Grau} and R. Flaskamp and Casta{\~n}eda, {J. R.} and I. Arocha and P. Rentschler and L. Lemme and C. Lara and E. Merino",

year = "1997",

language = "Espa{\~n}ol ",

volume = "22",

pages = "54--61",

journal = "Revista Neurologica Argentina",

issn = "0325-0938",

publisher = "Argentine Neurological Society",

number = "2",

}

Fornazzari, L, Alvarez, F, Gabrielli, H, Sastre, A, Fustinoni, O, Gold, L, Pangre, N, Roselli, D, Roselli, A, Chaskel, R, Hernández, RE, De Villavicencio Ojeda, A, Vidal, MG, Flaskamp, R, Castañeda, JR, Arocha, I, Rentschler, P, Lemme, L, Lara, C & Merino, E 1997, 'Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano', Revista Neurologica Argentina, vol. 22, no. 2, pp. 54-61.

TY - JOUR

T1 - Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano

AU - Fornazzari, L.

AU - Alvarez, F.

AU - Gabrielli, H.

AU - Sastre, A.

AU - Fustinoni, O.

AU - Gold, L.

AU - Pangre, N.

AU - Roselli, D.

AU - Roselli, A.

AU - Chaskel, R.

AU - Hernández, R. E.

AU - De Villavicencio Ojeda, A.

AU - Vidal, M. Grau

AU - Flaskamp, R.

AU - Castañeda, J. R.

AU - Arocha, I.

AU - Rentschler, P.

AU - Lemme, L.

AU - Lara, C.

AU - Merino, E.

PY - 1997

Y1 - 1997

N2 - This first multicenter, multinational, latinamerican, open study was designed to evaluate efficacy and safety of nimodipine in patients with Primary Degenerative Dementia-Alzheimer type (PDD-AD) and Multiinfarct Dementia (MID). The study ran for 12 weeks, and at baseline and every 4 weeks, the patients were evaluated with a battery of cognitive tests: Mini Mental State Examination (MMSE) and Trail Making Test (TMT-A), and also behavioral-functional scales like SCAG and RAGS-E. There was a significant difference in the majority of the test performances among baseline and at the end of the study in both groups. This significant improvement was also noticed independently by the caregivers assessed by the RAGS-E scale. The alleviation of behavioral symptoms in both groups, including anxiety, irritability, hostility, and paranoia, particularly in PDD-AD patients, makes us suggest that nimodipine could be used as an effective and safe drug to alleviate cognitive and behavioral symptoms in the two more common causes of dementia world wide.

AB - This first multicenter, multinational, latinamerican, open study was designed to evaluate efficacy and safety of nimodipine in patients with Primary Degenerative Dementia-Alzheimer type (PDD-AD) and Multiinfarct Dementia (MID). The study ran for 12 weeks, and at baseline and every 4 weeks, the patients were evaluated with a battery of cognitive tests: Mini Mental State Examination (MMSE) and Trail Making Test (TMT-A), and also behavioral-functional scales like SCAG and RAGS-E. There was a significant difference in the majority of the test performances among baseline and at the end of the study in both groups. This significant improvement was also noticed independently by the caregivers assessed by the RAGS-E scale. The alleviation of behavioral symptoms in both groups, including anxiety, irritability, hostility, and paranoia, particularly in PDD-AD patients, makes us suggest that nimodipine could be used as an effective and safe drug to alleviate cognitive and behavioral symptoms in the two more common causes of dementia world wide.

UR - http://www.scopus.com/inward/record.url?scp=0031460971&partnerID=8YFLogxK

M3 - Artículo

AN - SCOPUS:0031460971

SN - 0325-0938

VL - 22

SP - 54

EP - 61

JO - Revista Neurologica Argentina

JF - Revista Neurologica Argentina

IS - 2

ER -

Eficaci y tolerabilidad de nimodipino en el tratamiento de demencia degenerativa primaria y demencia vascular tipo infartos multiples. Estudio multicentrico latinoamericano

Abstract

Other files and links

Fingerprint

Cite this